EMA Authorised: Giapreza (angiotensin II acetate) — Paion Pharma GmbH

View source ↗

Summary

Giapreza (angiotensin II acetate) has been authorised by the EMA for adults with hypotension and shock, under Paion Pharma GmbH, with a decision date of 19 Sept…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypotension
• Shock

Drugs mentioned

• Giapreza (Angiotensin II)

Snippet

Status: Authorised. Therapeutic area: Hypotension;Shock. MAH: Paion Pharma GmbH. Decision date: 19/09/2024